content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Regenxbio Inc. (RGNX)

69.35
-2.20
(-3.08%)
Sep 11, 4:00PM EDT
content_middle

RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases.  RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.

Previous Close: 
25.70
Open: 
26.35
Bid: 
16.30
Ask: 
28.20
1yr Target Price: 
43.00
Day's Range: 
25.05 - 26.35
52wk Range: 
23.25 - 85.10
Volume: 
200875
Average Daily Volume: 
242272
Market Capitalization: 
2,240.60M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
32.31M
content_right